Leukemia, Acute Myeloid disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

AML MCID: LKM061 MIFTS: 83	Leukemia, Acute Myeloid (AML) Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Leukemia, Acute Myeloid

MalaCards integrated aliases for Leukemia, Acute Myeloid:

Name: Leukemia, Acute Myeloid ⁵⁷ ³⁸

Acute Myeloid Leukemia ³⁸ ¹² ⁷⁶ ⁵³ ⁷⁵ ³⁷ ²⁹ ⁶ ⁴³ ¹⁵

Leukemia, Acute Myelogenous ⁵⁷ ⁷⁵ ¹³ ⁴⁰

Acute Myelogenous Leukemia ¹² ⁷⁶ ⁵³ ¹⁵

Leukemia, Acute Myeloid, Susceptibility to ⁵⁷ ²⁹ ⁶

Acute Undifferentiated Leukemia ⁵⁹ ⁵⁵ ⁷³

Acute Myeloblastic Leukemia ¹² ⁷⁶ ⁷⁵

Acute Biphenotypic Leukemia ⁵⁹ ⁷³

Leukemia, Myelocytic, Acute ¹² ⁷³

Acute Myelocytic Leukemia ⁷⁶ ⁷⁵

Leukemia, Myeloid, Acute ⁴⁴ ⁴⁰

Aml ⁵⁷ ⁷⁵

Acute Myeloid Leukaemia with Myelodysplasia-Related Features ⁵⁹

Acute Myeloid Leukemia, Minimal Differentiation, Fab M0 ⁵⁹

Leukemia, Acute Myeloid, Reduced Survival in, Somatic ⁵⁷

Acute Myeloid Leukemia with Cebpa Somatic Mutations ⁵⁹

Acute Myeloid Leukemia with Multilineage Dysplasia ⁵⁹

Myeloid Leukemia, Acute, M4/m4eo Subtype, Somatic ⁵⁷

Aml with Myelodysplasia-Related Features ⁵⁹

Pure Familial Acute Myeloid Leukemia ⁵⁹

Leukemia, Acute Myeloid, Somatic ⁵⁷

Aml with Cebpa Somatic Mutations ⁵⁹

Inherited Acute Myeloid Leukemia ⁵⁹

Acute Non-Lymphoblastic Leukemia ⁷⁵

Acute Myeloid Leukemia, Somatic ⁵⁷

Aml with Multilineage Dysplasia ⁵⁹

Acute Non-Lymphocytic Leukemia ⁷⁵

Aml - Acute Myeloid Leukemia ¹²

Bilineal Acute Leukemia ⁵⁹

Pure Familial Aml ⁵⁹

Inherited Aml ⁵⁹

Familial Aml ⁵⁹

Characteristics:

Orphanet epidemiological data:

⁵⁹

acute myeloid leukaemia with myelodysplasia-related features
Age of onset: Adult;

OMIM:

⁵⁷

Inheritance:
autosomal dominant
somatic mutation

Miscellaneous:
evidence of anticipation
mean onset age 57 years, 32 years and 13 years in successive generations
many genes with somatic mutation

HPO:

³²

leukemia, acute myeloid:
Inheritance autosomal dominant inheritance

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Blood diseases Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³³ ³⁴

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Leukaemia of unspecified cell type

Acute leukaemia of unspecified cell type

Myeloid leukaemia

Acute myeloblastic leukaemia [AML]

Acute myeloid leukaemia with 11q23-abnormality

Acute myeloid leukaemia with multilineage dysplasia

Orphanet: ⁵⁹

Rare haematological diseases

External Ids:

OMIM ⁵⁷ 601626

Disease Ontology ¹² DOID:9119

ICD10 ³³ C92.0 C92.00 C92.6 more

ICD9CM ³⁵ 205.0

MeSH ⁴⁴ D015470

NCIt ⁵⁰ C27753 C3171

SNOMED-CT ⁶⁸ 17788007 91861009

Orphanet ⁵⁹ ORPHA319480 ORPHA319465 ORPHA86845 more

ICD10 via Orphanet ³⁴ C92.0 C92.8 C95.0

UMLS via Orphanet ⁷⁴ C1292773 C0023464 C0280141 more

MESH via Orphanet ⁴⁵ D015456

MedGen ⁴² C0023467 C3275959

KEGG ³⁷ H00003

SNOMED-CT via HPO ⁶⁹ 263681008 413443009 240305000

UMLS ⁷³ C0023467 C0023464 C0280141

Sources

Summaries for Leukemia, Acute Myeloid

MedlinePlus : ⁴³ Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, however, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. In acute myeloid leukemia (AML), there are too many of a specific type of white blood cell called a myeloblast. AML is the most common type of acute leukemia in adults. This type of cancer usually gets worse quickly if it is not treated. Possible risk factors include smoking, previous chemotherapy treatment, and exposure to radiation. Symptoms of AML include: Fever Shortness of breath Easy bruising or bleeding Bleeding under the skin Weakness or feeling tired Weight loss or loss of appetite Tests that examine the blood and bone marrow diagnose AML. Treatments include chemotherapy, other drugs, radiation therapy, stem cell transplants, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. Once the leukemia is in remission, you need additional treatment to make sure that it does not come back. NIH: National Cancer Institute

MalaCards based summary : Leukemia, Acute Myeloid, also known as acute myeloid leukemia, is related to core binding factor acute myeloid leukemia and leukemia, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Leukemia, Acute Myeloid is CEBPA (CCAAT Enhancer Binding Protein Alpha), and among its related pathways/superpathways are Acute myeloid leukemia and Transcriptional misregulation in cancer. The drugs Folotyn and Ixempra have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are acute myeloid leukemia and Reduced mammosphere formation

Disease Ontology : ¹² A myeloid leukemia that is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells.

NIH Rare Diseases : ⁵³ Acute myeloid leukemia (AML) is a cancer that affects the blood and bone marrow. Conditions are generally called "acute" when they develop quickly and have an aggressive course. The signs and symptoms of AML vary but may include easy bruising; bone pain or tenderness; fatigue; fever; frequent nosebleeds; bleeding from the gums; shortness of breath; and/or weightloss. AML is one of the most common types of leukemia among adults and is rarely diagnosed in people under age 40. There are many potential causes of AML such as certain blood disorders, inheritedsyndromes, environmental exposures, and drug exposures; however, most people who develop AML have no identifiable risk factor. Treatment may include a combination of chemotherapy, radiation therapy, bone marrow transplant and/or other drug therapy.

UniProtKB/Swiss-Prot : ⁷⁵ Leukemia, acute myelogenous: A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.

Wikipedia : ⁷⁶ Acute myeloblastic leukemia is a form of myeloid leukemia affecting... more...

Description from OMIM: 601626

Sources

Related Diseases for Leukemia, Acute Myeloid

Diseases in the Myeloid Leukemia family:

Leukemia, Acute Myeloid	Leukemia, Chronic Myeloid
Subacute Myeloid Leukemia	Acute Myeloid Leukemia with T(9;11)(p22;q23)
Acute Myeloid Leukemia with T(6;9)(p23;q34)

Diseases related to Leukemia, Acute Myeloid via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 625)

#	Related Disease	Score	Top Affiliating Genes
1	core binding factor acute myeloid leukemia	33.7	CEBPA FLT3 JAK2 KIT KRAS NRAS
2	leukemia	33.5	CEBPA CSF3R ETV6 FLT3 JAK2 KIT
3	acute myeloblastic leukemia with maturation	33.5	FLT3 KIT NPM1
4	cytogenetically normal acute myeloid leukemia	33.5	CEBPA FLT3 NPM1
5	acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)	33.2	ETV6 FLT3 KIT RUNX1
6	acute erythroid leukemia	33.1	CEBPA GATA2 JAK2 PICALM
7	acute leukemia	32.9	CEBPA ETV6 FLT3 JAK2 KIT MLLT10
8	acute myeloblastic leukemia without maturation	32.8	FLT3 NPM1
9	acute myeloid leukemia with t(8;21)(q22;q22) translocation	32.7	CEBPA FLT3 KIT RUNX1
10	myeloid leukemia	32.4	CEBPA CSF3R DNMT3A ETV6 FLT3 GATA2
11	myeloid sarcoma	31.2	FLT3 KIT NPM1
12	lymphoid leukemia	31.2	ETV6 FLT3 JAK2
13	leukemia, chronic myeloid	30.9	CSF3R ETV6 FLT3 GATA2 JAK2 KIT
14	myelodysplastic syndrome	30.8	CEBPA CSF3R DNMT3A ETV6 FLT3 GATA2
15	myeloproliferative neoplasm	30.8	JAK2 KIT PTPN11
16	precursor t-cell acute lymphoblastic leukemia	30.8	ETV6 FLT3 MLLT10 NUP214 PICALM
17	chronic myelomonocytic leukemia	30.7	CSF3R DNMT3A ETV6 FLT3 JAK2 KIT
18	aleukemic leukemia cutis	30.6	FLT3 NPM1 RUNX1
19	myeloma, multiple	30.6	JAK2 KIT KRAS NRAS PTPN11
20	leukemia, chronic lymphocytic 2	30.6	KRAS NRAS PTPN11
21	severe congenital neutropenia	30.6	CSF3R JAK2 PTPN11
22	acute promyelocytic leukemia	30.5	CEBPA CSF3R FLT3 NPM1 NRAS RUNX1
23	myelodysplastic myeloproliferative cancer	30.5	CSF3R JAK2 NRAS PTPN11
24	juvenile myelomonocytic leukemia	30.5	DNMT3A FLT3 JAK2 KRAS NRAS PTPN11
25	leukemia, acute lymphoblastic	30.5	ETV6 FLT3 PICALM RUNX1
26	atypical chronic myeloid leukemia	30.4	CSF3R JAK2 RUNX1
27	8p11 myeloproliferative syndrome	30.4	FLT3 KIT RUNX1
28	aplastic anemia	30.4	CSF3R FLT3 GATA2 NRAS TERT
29	acute t cell leukemia	30.4	LPP MLLT10 NUP214
30	childhood leukemia	30.4	ETV6 PTPN11 RUNX1
31	subacute myeloid leukemia	30.3	FLT3 JAK2
32	familial acute myeloid leukemia with mutated cebpa	12.6
33	acute biphenotypic leukemia	12.5
34	therapy related acute myeloid leukemia and myelodysplastic syndrome	12.4
35	cebpa-associated familial acute myeloid leukemia	12.3
36	aml with myelodysplasia-related features	12.1
37	megakaryocytic leukemia	11.9
38	lymphedema, primary, with myelodysplasia	11.7
39	platelet disorder, familial, with associated myeloid malignancy	11.6
40	acute monoblastic leukemia	11.6
41	acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2)	11.5
42	acute myeloid leukemia with minimal differentiation	11.5
43	myelodysplastic syndrome with excess blasts	11.5
44	acute non lymphoblastic leukemia	11.3
45	shwachman-diamond syndrome 2	11.3
46	erythroleukemia, familial	11.3
47	acute myeloid leukemia with t(8;16)(p11;p13) translocation	11.3
48	acute myeloid leukemia with t(9;11)(p22;q23)	11.3
49	acute myeloid leukemia with t(6;9)(p23;q34)	11.3
50	acute myeloid leukemia with npm1 somatic mutations	11.3

Graphical network of the top 20 diseases related to Leukemia, Acute Myeloid:

Sources

Symptoms & Phenotypes for Leukemia, Acute Myeloid

Symptoms via clinical synopsis from OMIM:

⁵⁷

Hematology:
acute myelogenous leukemia (aml)

Clinical features from OMIM:

601626

Human phenotypes related to Leukemia, Acute Myeloid:

³²

#	Description	HPO Frequency	HPO Source Accession
1	acute myeloid leukemia ³²		HP:0004808

UMLS symptoms related to Leukemia, Acute Myeloid:

angina pectoris, edema, chest pain

GenomeRNAi Phenotypes related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Reduced mammosphere formation	GR00396-S	9.28	CEBPA CSF3R DNMT3A ETV6 KRAS NRAS

MGI Mouse Phenotypes related to Leukemia, Acute Myeloid:

⁴⁶ (show all 19)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.53	CEBPA CSF3R DNMT3A ETV6 FLT3 GATA2
2	hematopoietic system	MP:0005397	10.43	CEBPA CHIC2 CSF3R DNMT3A ETV6 FLT3
3	endocrine/exocrine gland	MP:0005379	10.39	CEBPA CHIC2 CSF3R DNMT3A ETV6 FLT3
4	homeostasis/metabolism	MP:0005376	10.39	CEBPA DNMT3A ETV6 FLT3 GATA2 JAK2
5	mortality/aging	MP:0010768	10.39	CEBPA CHIC2 CSF3R DNMT3A ETV6 FLT3
6	growth/size/body region	MP:0005378	10.38	CEBPA DNMT3A ETV6 FLT3 GATA2 JAK2
7	immune system	MP:0005387	10.37	CEBPA CHIC2 CSF3R DNMT3A ETV6 FLT3
8	embryo	MP:0005380	10.34	DNMT3A ETV6 GATA2 JAK2 KIT KRAS
9	cardiovascular system	MP:0005385	10.32	CEBPA CHIC2 CSF3R ETV6 GATA2 KIT
10	integument	MP:0010771	10.22	CEBPA CHIC2 ETV6 JAK2 KIT KRAS
11	liver/biliary system	MP:0005370	10.16	CEBPA GATA2 JAK2 KIT KRAS NPM1
12	neoplasm	MP:0002006	10.14	CEBPA ETV6 FLT3 JAK2 KIT KRAS
13	digestive/alimentary	MP:0005381	10.11	CEBPA ETV6 KIT KRAS NRAS PTPN11
14	normal	MP:0002873	10.02	CEBPA ETV6 GATA2 JAK2 KIT KRAS
15	no phenotypic analysis	MP:0003012	9.97	CEBPA ETV6 FLT3 KIT KRAS NRAS
16	reproductive system	MP:0005389	9.9	CEBPA CHIC2 CSF3R DNMT3A GATA2 JAK2
17	pigmentation	MP:0001186	9.73	CHIC2 KIT KRAS NRAS PICALM PTPN11
18	skeleton	MP:0005390	9.61	FLT3 JAK2 KIT KRAS NRAS PTPN11
19	vision/eye	MP:0005391	9.23	CEBPA CHIC2 KIT KRAS NPM1 NRAS

Sources

Drugs & Therapeutics for Leukemia, Acute Myeloid

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁸	Company	Approval Date
1	Folotyn ¹⁸ ⁴⁹	PRALATREXATE	Allos Therapeutics	September 2009
FDA Label: Folotyn Disease/s that Drug Treats:peripheral T-cell lymphoma Indications and Usage: ¹⁸ FOLOTYN is a folate analog metabolic inhibitor indicated for the treatment ofpatients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Thisindication is based on overall response rate. Clinical benefit such asimprovement in progression-free survival or overall survival has not beendemonstrated. (1) DrugBank Targets: ¹⁶ 1. Dihydrofolate reductase;2. Thymidylate synthase Mechanism of Action: ¹⁸ Target: dihydrofolate reductase Action: inhibitor FDA: Pralatrexate is a folate analog metabolic inhibitor that competitively inhibits dihydrofolate reductase. It is also acompetitive inhibitor for polyglutamylation by the enzyme folylpolyglutamyl synthetase. This inhibition resultsin the depletion of thymidine and other biological molecules the synthesis of which depends on single carbontransfer.
2	Ixempra ¹⁸ ⁴⁹	IXABEPILONE	Bristol-Myers Squibb	October 2007
FDA Label: Ixempra Disease/s that Drug Treats:Breast cancer Indications and Usage: ¹⁸ IXEMPRA, a microtubule inhibitor, in combination with capecitabine isindicated for the treatment of metastatic or locally advanced breastcancer in patients after failure of an anthracycline and a taxane (1). IXEMPRA as monotherapy is indicated for the treatment of metastaticor locally advanced breast cancer in patients after failure of ananthracycline, a taxane, and capecitabine (1). DrugBank Targets: ¹⁶ 1. Tubulin beta-3 chain Mechanism of Action: ¹⁸ Target: Î²-tubulin subunits on microtubules Action: suppressor of dynamics FDA: Ixabepilone is a semi-synthetic analog of epothilone B. Ixabepilone binds directlyto Î²-tubulin subunits on microtubules, leading to suppression of microtubule dynamics.Ixabepilone suppresses the dynamic instability of Î±Î²-II and Î±Î²-III microtubules.Ixabepilone possesses low in vitro susceptibility to multiple tumor resistance mechanisms including efflux transporters, such as MRP-1 and P-glycoprotein (P-gp). Ixabepiloneblocks cells in the mitotic phase of the cell division cycle, leading to cell death.
3	Leukine ¹⁸	SARGRAMOSTIM	Immunex	on November 24, 1995/ November 1996
FDA Label: Leukine Disease/s that Drug Treats:transplantation/ replenishment of white blood cells, fungal infections Indications and Usage: ¹⁸ DrugBank Targets: ¹⁶ 1. Granulocyte-macrophage colony-stimulating factor receptor subunit alpha;2. Interleukin-3 receptor subunit alpha;3. Cytokine receptor common subunit beta;4. Syndecan-2;5. Bone marrow proteoglycan Mechanism of Action: ¹⁸ Target: - Action: - FDA: -
4	Mylotarg ¹⁸ ⁴⁹	GEMTUZUMAB OZOGAMICIN	Wyeth	May 2000
FDA Label: Mylotarg Disease/s that Drug Treats:Acute Myeloid Leukemia (AML) Indications and Usage: ¹⁸ Mylotarg is indicated for the treatment of patients with CD33 positive acute myeloid leukemia infirst relapse who are 60 years of age or older and who are not considered candidates for othercytotoxic chemotherapy. The safety and efficacy of Mylotarg in patients with poor performancestatus and organ dysfunction has not been established.The effectiveness of Mylotarg is based on OR rates (see CLINICAL STUDIES section). Thereare no controlled trials demonstrating a clinical benefit, such as improvement in disease-relatedsymptoms or increased survival, compared to any other treatment. DrugBank Targets: ¹⁶ 1. Myeloid cell surface antigen CD33;2. Low affinity immunoglobulin gamma Fc region receptor III-B;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Low affinity immunoglobulin gamma Fc region receptor III-A;8. Complement C1s subcomponent;9. High affinity immunoglobulin gamma Fc receptor I;10. Low affinity immunoglobulin gamma Fc region receptor II-a;11. Low affinity immunoglobulin gamma Fc region receptor II-b;12. Low affinity immunoglobulin gamma Fc region receptor II-c Mechanism of Action: ¹⁸ Target: CD33 antigen expressed byhematopoietic cells Action: binds to form complex that then causes a break in the DNA double strand FDA: Mylotarg is directed against the CD33 antigen expressed byhematopoietic cells. Binding of the anti-CD33 antibody portion of Mylotarg with the CD33antigen results in the formation of a complex that is internalized. Upon internalization, thecalicheamicin derivative is released inside the lysosomes of the myeloid cell. The releasedcalicheamicin derivative binds to DNA in the minor groove resulting in DNA double strandbreaks and cell death.Gemtuzumab ozogamicin is cytotoxic to the CD33 positive HL-60 human leukemia cell line.Gemtuzumab ozogamicin produces significant inhibition of colony formation in cultures of adultleukemic bone marrow cells. The cytotoxic effect on normal myeloid precursors leads tosubstantial myelosuppression, but this is reversible because pluripotent hematopoietic stem cellsare spared. In preclinical animal studies, gemtuzumab ozogamicin demonstrates antitumoreffects in the HL-60 human promyelocytic leukemia xenograft tumor in athymic mice.
5	Arcapta ¹⁸	INDACATEROL MALEATE	Novartis	July 2011
FDA Label: Arcapta Disease/s that Drug Treats:airflow obstruction resulting from chronic obstructive pulmonary disease Indications and Usage: ¹⁸ ARCAPTA NEOHALER is a long-acting beta2-adrenergic agonist indicated for: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. (1.1) Important limitations: * ARCAPTA NEOHALER is NOT indicated to treat acute deteriorations of chronic obstructive pulmonary disease. (1.2) * ARCAPTA NEOHALER is NOT indicated for asthma. (1.2) DrugBank Targets: ¹⁶ Beta-2 adrenergic receptor Mechanism of Action: ¹⁸ Target: beta2-adrenergic Action: agonist FDA: Indacaterol is a long-acting beta2-adrenergic agonist. When inhaled, indacaterol acts locally in the lung as a bronchodilator. Although beta2-receptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1-receptors are the predominant receptors in the heart, there are also beta2-adrenergic receptors in the human heart comprising 10%-50% of the total adrenergic receptors. The precise function of these receptors is not known, but their presence raises the possibility that even highly selective beta2- adrenergic agonists may have cardiac effects. The pharmacological effects of beta2-adrenoceptor agonist drugs, including indacaterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3â, 5â-adenosine monophosphate (cyclic monophosphate). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle. In vitro studies have shown that indacaterol has more than 24-fold greater agonist activity at beta2-receptors compared to beta1-receptors and 20-fold greater agonist activity compared to beta3-receptors. This selectivity profile is similar to formoterol. The clinical significance of these findings is unknown.

Drugs for Leukemia, Acute Myeloid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 676)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Cytarabine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

147-94-4

6253

Idarubicin

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

58957-92-9

42890

Vidarabine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

24356-66-9

32326 21704

Fludarabine

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

75607-67-9, 21679-14-1

30751

Decitabine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

2353-33-5

451668

Azacitidine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

320-67-2

9444

Daunorubicin

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

20830-81-3

30323

Mitoxantrone

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

65271-80-9

4212

Etoposide

Approved

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

33419-42-0

36462

Prednisone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1

53-03-2

5865

Lenograstim

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

135968-09-1

Benzocaine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

94-09-7, 1994-09-7

2337

tannic acid

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Topotecan

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

123948-87-8, 119413-54-6

60700

Amsacrine

Approved, Investigational

Phase 4,Phase 3,Phase 1,Phase 2

51264-14-3

2179

Aldesleukin

Approved

Phase 4,Phase 3,Phase 2,Phase 1

85898-30-2, 110942-02-4

Miconazole

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

22916-47-8

4189

Lenalidomide

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

191732-72-6

216326

Cyclophosphamide

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

6055-19-2, 50-18-0

2907

Thiotepa

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

52-24-4

5453

Dopamine

Approved

Phase 4,Phase 3,Phase 2,Phase 1

51-61-6, 62-31-7

681

Histamine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

51-45-6, 75614-87-8

774

Posaconazole

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

171228-49-2

147912

Micafungin

Approved, Investigational

Phase 4,Phase 2

235114-32-6

3081921 477468

Nicotine

Approved

Phase 4,Not Applicable

54-11-5

942 89594

Bupropion

Approved

Phase 4,Phase 2

34841-39-9, 34911-55-2

444

Vitamin D

Approved, Nutraceutical, Vet_approved

Phase 4,Phase 2

1406-16-2

Vitamin D3

Approved, Nutraceutical

Phase 4,Phase 2

67-97-0

5280795 6221

Ergocalciferol

Approved, Nutraceutical

Phase 4,Phase 2

50-14-6

5280793

Molgramostim

Investigational

Phase 4,Phase 3

99283-10-0

Aclarubicin

Investigational

Phase 4,Phase 2,Phase 1,Not Applicable

57576-44-0

451415

Anti-Bacterial Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antiviral Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antimetabolites

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Anti-Infective Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Immunosuppressive Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antimetabolites, Antineoplastic

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Immunologic Factors

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Topoisomerase Inhibitors

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antibiotics, Antitubercular

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Analgesics

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Peripheral Nervous System Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Etoposide phosphate

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Antineoplastic Agents, Phytogenic

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Interferon-alpha

Phase 4,Phase 2,Phase 1,Not Applicable

interferons

Phase 4,Phase 2,Phase 1,Not Applicable

Cyclosporins

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Gemtuzumab

Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1

topoisomerase I inhibitors

Phase 4,Phase 2,Phase 1

Adjuvants, Immunologic

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 2605)

#	Name	Status	NCT ID	Phase	Drugs
1	Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia	Unknown status	NCT02277847	Phase 4	Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
2	AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy	Unknown status	NCT02024308	Phase 4	Fludarabine;Cytarabine
3	Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation	Unknown status	NCT01806116	Phase 4	decitabine
4	3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia	Unknown status	NCT01587430	Phase 4	high dose ARA-C;standard dose ARA-C
5	Efficacy of G-CSF-Priming in Elderly AML Patients	Unknown status	NCT00199147	Phase 4	Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
6	Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT	Unknown status	NCT02027064	Phase 4	Interferon-alpha
7	Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia	Unknown status	NCT01997372	Phase 4	ATG
8	Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells（Umbilical Cord Derived）	Unknown status	NCT02218437	Phase 4	MSC+ATG
9	LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)	Completed	NCT01041040	Phase 4	gemtuzumab
10	Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years	Completed	NCT00464217	Phase 4	ARA-C;Idarubicin;Leucomax
11	Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Completed	NCT00488709	Phase 4	Topotecan;Fludarabine;Cytarabine
12	Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia	Completed	NCT01819792	Phase 4
13	Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21)	Active, not recruiting	NCT03026842	Phase 4	Decitabine;Daunorubicin, Cytarabine;Mitoxantrone, Cytarabine;Aclacinomycin, Cytarabine
14	SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia	Completed	NCT00487448	Phase 4	Fludarabine;Cytarabine;G-CSF;Idarubicin
15	AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years	Completed	NCT00180102	Phase 4	Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
16	Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia	Completed	NCT01347996	Phase 4	histamine dihydrochloride and IL-2
17	Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients	Recruiting	NCT03150134	Phase 4	Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
18	Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome	Completed	NCT01200355	Phase 4	micafungin;posaconazole
19	Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML	Recruiting	NCT02926586	Phase 4	Fludarabine;Cytarabine
20	AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients	Completed	NCT00180115	Phase 4	Cytarabine Dosage
21	LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)	Terminated	NCT01198054	Phase 4	Lenalidomide
22	Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraC	Completed	NCT00180167	Phase 4	randomization between two established Chemotherapies
23	Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients	Recruiting	NCT02267993	Phase 4	recombinant human thrombopoietin
24	Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML	Not yet recruiting	NCT03727750	Phase 4	Gemtuzumab Ozogamicin
25	Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia	Completed	NCT00304447	Phase 4	Mylotarg
26	Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections	Recruiting	NCT02805946	Phase 4	posaconazole
27	King's Invasive Aspergillosis Study II	Active, not recruiting	NCT02875743	Phase 4	Posaconazole
28	Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)	Completed	NCT00686543	Phase 4	Posaconazole
29	Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia	Recruiting	NCT02618109	Phase 4
30	A Rollover Study to Provide Continued Treatment With Eltrombopag	Active, not recruiting	NCT01957176	Phase 4	ELT
31	G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor	Recruiting	NCT02933333	Phase 4
32	Bone Marrow Transplantation in Treating Patients With Hematologic Cancer	Completed	NCT00003398	Phase 4	cyclophosphamide;thiotepa
33	A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT	Enrolling by invitation	NCT03176849	Phase 4
34	Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking	Completed	NCT00666978	Phase 4	bupropion hydrochloride
35	Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking	Completed	NCT00365508	Phase 4	nicotine lozenge;nicotine patch
36	the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient	Unknown status	NCT01766375	Phase 3	Cyclosporin A,mycophenolate mofetil,Methotrexate
37	HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia	Unknown status	NCT01484171	Phase 3	idarubicin
38	Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia	Unknown status	NCT00342316	Phase 3
39	Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia	Unknown status	NCT02244658	Phase 3	rhTPO
40	Safety and Efficacy Study of Microtransplantation to Treat Elderly Acute Myeloid Leukemia	Unknown status	NCT02171117	Phase 3
41	Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients	Unknown status	NCT01633099	Phase 3	Decitabine
42	Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML)	Unknown status	NCT01145846	Phase 3	Cytarabine plus Daunorubicin [Arm II (AD regimen)]
43	Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T	Unknown status	NCT00209833	Phase 2, Phase 3	Cytarabine;Idarubicin;Etoposide;Fludarabine;G-CSF;Daunorubicine
44	Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML	Unknown status	NCT02474290	Phase 2, Phase 3	Sorafenib
45	Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid Leukaemia	Unknown status	NCT00224614	Phase 3
46	Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study	Unknown status	NCT00715637	Phase 3	Daunorubicin and Cytarabine;Amonafide and Cytarabine
47	Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia	Unknown status	NCT00002658	Phase 3	amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
48	Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia	Unknown status	NCT00003602	Phase 3	cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
49	Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents	Unknown status	NCT00111345	Phase 2, Phase 3	Anthracyclines;liposomal daunorubicin;2-CDA;AI
50	Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia	Unknown status	NCT00006045	Phase 3	cytarabine;etoposide;mitoxantrone hydrochloride

Search NIH Clinical Center for Leukemia, Acute Myeloid

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :

cyclophosphamide

etoposide

etoposide phosphate

idarubicin

idarubicin hydrochloride

mitoxantrone

mitoxantrone hydrochloride

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Leukemia, Acute Myeloid cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Leukemia, Acute Myeloid:

	Hemacord�, umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
	Hematopoietic stem cells for treatment of hematologic malignancies
	NiCord�, umbilical cord blood-derived stem/progenitor cells for hemotological diseases
	Peripheral blood stem cells for treatment of hematologic malignancies
	StemEx�, umbilical cord blood stem/progenitor cells for hematological diseases

Embryonic/Adult Cultured Cells Related to Leukemia, Acute Myeloid:

	Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD�) PMIDs: 9828244
	Bone marrow-derived hematopoietic stem cells
	Umbilical cord blood-derived stem cells (NiCord) PMIDs: 22198152
	Peripheral blood-derived hematopoietic stem cells (family)
	Umbilical cord blood stem/progenitor cells (Stemex) PMIDs: 18209724

Cochrane evidence based reviews: leukemia, myeloid, acute

Sources

Genetic Tests for Leukemia, Acute Myeloid

Genetic tests related to Leukemia, Acute Myeloid:

#	Genetic test	Affiliating Genes
1	Acute Myeloid Leukemia ²⁹	CBFB CEBPA CHIC2 DNMT3A ETV6 FLT3 GATA2 JAK2 KIT KRAS LPP MLF1 MLLT10 NPM1 NSD1 NSD3 NUP214 PICALM RUNX1 SH3GL1 TERT
2	Leukemia, Acute Myeloid, Susceptibility to ²⁹

Sources

Anatomical Context for Leukemia, Acute Myeloid

MalaCards organs/tissues related to Leukemia, Acute Myeloid:

⁴¹

Myeloid, Bone, Bone Marrow, T Cells, Nk Cells, Testes, Monocytes

Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Leukemia, Acute Myeloid:

#	Tissue Anatomical CompartmentCell	Relevance
1	Blood Hematopoietic Bone Marrow Common Myeloid Progenitor Cells	Affected by disease
2	Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells	Potential therapeutic candidate

Sources

Publications for Leukemia, Acute Myeloid

Articles related to Leukemia, Acute Myeloid:

(show top 50) (show all 5993)

#	Title	Authors	Year
1	Hearing Status in Survivors of Childhood Acute Myeloid Leukemia Treated With Chemotherapy Only: A NOPHO-AML Study. ( 30550508 )	Skou AS...Nordic Society of Pediatric Hematology and Oncology (NOPHO)	2019
2	TUG1 confers Adriamycin resistance in acute myeloid leukemia by epigenetically suppressing miR-34a expression via EZH2. ( 30551433 )	Li Q...Wang J	2019
3	Allogeneic hematopoietic cell transplantation in chemotherapy-induced aplasia in children with high-risk acute myeloid leukemia or myelodysplasia. ( 30318867 )	Kussman A...Petrovic A	2019
4	ADAMTS-13 activity reduction in plasma of acute myeloid leukemia predicts poor prognosis after bone marrow transplantation. ( 30322352 )	Liu C...Wang H	2019
5	Comparison of conditioning regimens for autologous stem cell transplantation in children with acute myeloid leukemia: A nationwide retrospective study in Japan. ( 30270523 )	Sakaguchi H...Pediatric AML Working Group of the Japan Society for Hematopoietic Cell Transplantation	2019
6	FLT3 inhibitors in acute myeloid leukemia: Current and future. ( 30270754 )	Thomas CM...Campbell P	2019
7	Wogonoside impedes the progression of acute myeloid leukemia through inhibiting bone marrow angiogenesis. ( 30105796 )	Lin B...Lu N	2019
8	Stone RM, Manley PW, Larson RA, Capdeville R. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. <i>Blood Adv</i>. 2017;2(4):444-453. ( 29618463 )		2018
9	High Expression of TET1 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia From Two Cohorts. ( 29402726 )	Wang J....Jin J.	2018
10	Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia. ( 29468060 )	Gurnari C....Voso M.T.	2018
11	Mutation profile and associated clinical features in Chinese patients with cytogenetically normal acute myeloid leukemia. ( 29573577 )	Wang S....Chen B.	2018
12	Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation. ( 29330391 )	Devillier R....Mohty M.	2018
13	Characteristics of early acute respiratory distress syndrome in newly diagnosed acute myeloid leukemia. ( 29431568 )	Van de Louw A....Claxton D.F.	2018
14	A regulatory circuitry between miR-193a/miR-600 and WT1 enhances leukemogenesis in acute myeloid leukemia. ( 29452230 )	Li H....Gao S.	2018
15	Monitoring of clonal evolution of double C-KIT exon 17 mutations by Droplet Digital PCR in patients with core-binding factor acute myeloid leukemia. ( 29705537 )	Tan Y....Wang H.	2018
16	Editorial Comment to Therapy-related acute myeloid leukemia and myelodysplastic syndrome among refractory germ cell tumor patients. ( 29869384 )	Kishida T.	2018
17	MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin. ( 29976747 )	Seipel K....Pabst T.	2018
18	Vacuolar ATPase as a possible therapeutic target in human acute myeloid leukemia. ( 29168399 )	AasebA...Bruserud A.9.	2018
19	High expression of INHBA is an adverse prognostic factor for de novo acute myeloid leukemia. ( 28836868 )	Si T....Zhou J.X.	2018
20	Pilot Study on Mass Spectrometry-Based Analysis of the Proteome of CD34a8_CD123a8_ Progenitor Cells for the Identification of Potential Targets for Immunotherapy in Acute Myeloid Leukemia. ( 29439554 )	Schmidt J.R....Heidenreich F.	2018
21	Patient-reported outcomes in acute myeloid leukemia: Where are we now? ( 28888621 )	Buckley S.A....Lyman G.H.	2018
22	A case of chronic eosinophilic leukemia with secondary transformation to acute myeloid leukemia. ( 29892549 )	Hofmans M....Moors I.	2018
23	Characteristics of NK cells from leukemic microenvironment in MLL-AF9 induced acute myeloid leukemia. ( 29154208 )	Yang F....Zheng G.	2018
24	Regulation of Expression of CEBP Genes by Variably Expressed Vitamin D Receptor and Retinoic Acid Receptor I+ in Human Acute Myeloid Leukemia Cell Lines. ( 29966306 )	Marchwicka A....Marcinkowska E.	2018
25	Persistent cytogenetic abnormalities in patients undergoing intensive chemotherapy for acute myeloid leukemia. ( 28540755 )	Saini L....Sandhu I.	2018
26	Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia. ( 29843224 )	Zahran A.M....Hetta H.F.	2018
27	Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. ( 29247780 )	Shimoni A....Nagler A.	2018
28	The interference of genetic associations in establishing the prognostic value of the immunophenotype in acute myeloid leukemia. ( 28646564 )	van Solinge T.S....Schuurhuis G.J.	2018
29	Q482H mutation of procaspase-8 in acute myeloid leukemia abolishes caspase-8-mediated apoptosis by impairing procaspase-8 dimerization. ( 29191655 )	Li M....Yang X.	2018
30	Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis. ( 29928481 )	Calmettes C....Dumas P.Y.	2018
31	Successful Treatment of Cytogenetically Normal Acute Myeloid Leukemia With Ten-Eleven Translocation 2-Isocitrate Dehydrogenase 2 and Additional Sex Comb-like 1-Nucleophosmin Co-mutations by HLA Haploidentical Stem Cell Transplantation: A Case Report and Literature Review. ( 29661468 )	Liu Y....Gu W.Y.	2018
32	Outcome of patient with high-risk chronic myelomonocytic leukemia, treated with decitabine prior to transformation to acute myeloid leukemia: A case report. ( 29731877 )	Liu H....Liu B.	2018
33	Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). ( 29978286 )	Konuma T....Yano S.	2018
34	Acute Progressive Visual Loss in a Case of Acute Myeloid Leukemia: Challenges in the Utility of Molecular Tests in Early Diagnose of Cytomegalovirus Retinitis. ( 29560000 )	Amanati A....Zekavat O.R.	2018
35	Therapy-related Acute Myeloid Leukemia After the Treatment of Primary Solid Cancer in Children: A Single-center Experience. ( 29200163 )	Hong K.T....Shin H.Y.	2018
36	Lower expression of bone marrow miR-122 is an independent risk factor for overall survival in cytogenetically normal acute myeloid leukemia. ( 29627222 )	Zhang T.J....Qian J.	2018
37	Cytomegalovirus serostatus affects autoreactive NK cells and outcomes of IL2-based immunotherapy in acute myeloid leukemia. ( 29980537 )	Bernson E....Thoren F.B.	2018
38	Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+). ( 28838276 )	Falantes J....Ramos F.	2018
39	Multiple small bowel perforations due to invasive aspergillosis in a patient with acute myeloid leukemia: case report and a systematic review of the literature. ( 29357049 )	Di Franco G....Morelli L.	2018
40	Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. ( 29321554 )	Saygin C....Advani A.S.	2018
41	<i>NPM1</i> Mutation Analysis in Acute Myeloid Leukemia: Comparison of Three Techniques - Sanger Sequencing, Pyrosequencing, and Real-Time Polymerase Chain Reaction. ( 29129825 )	Kumar D....Saikia K.K.	2018
42	Initial therapy for acute myeloid leukemia in older patients: principles of care. ( 28573900 )	Bhatt V.R....Maness L.J.	2018
43	Nucleophosmin-1 regions associated with acute myeloid leukemia interact differently with lipid membranes. ( 29330024 )	De Santis A....Marasco D.	2018
44	CD16+NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice. ( 29976748 )	Williams B.A....Keating A.	2018
45	A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. ( 29119643 )	Deangelo D.J....Ballen K.K.	2018
46	Acute external otitis as debut of acute myeloid leukemia - A case and review of the literature. ( 29447882 )	Slengerik-Hansen J....Ovesen T.	2018
47	NSG-S mice for acute myeloid leukemia, yes. For myelodysplastic syndrome, no. ( 29866886 )	Griessinger E....Andreeff M.	2018
48	Protracted Clonal Trajectory of a <i>JAK2</i> V617F-Positive Myeloproliferative Neoplasm Developing during Long-Term Remission from Acute Myeloid Leukemia. ( 29854499 )	Langabeer S.E....Murphy P.T.	2018
49	Measurable residual disease, conditioning regimen intensity and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. ( 29981272 )	Gilleece M.H....Nagler A.	2018
50	Outcomes of measurable residual disease in pediatric acute myeloid leukemia pre- and post-hematopoietic stem cell transplant: validation of difference from normal flow cytometry with chimerism studies and Wilms tumor 1 gene expression. ( 29933069 )	Jacobsohn D.A....Pulsipher M.A.	2018

Sources

Genes for Leukemia, Acute Myeloid

Genes related to Leukemia, Acute Myeloid (38 elite genes):

(show top 50) (show all 209)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	CEBPA	CCAAT Enhancer Binding Protein Alpha	Protein Coding	1725.04	Molecular basis known ⁵⁷ Pathogenic ⁶ Causative somatic mutation ⁵⁹ Causative variation ⁷⁵ Genetic Tests ²⁹ Unconfirmed association ⁵⁷ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	11242107 20963938 22138009 (more) 23970018 12661007
2	GATA2	GATA Binding Protein 2	Protein Coding	1425.34	Molecular basis known ⁵⁷ Pathogenic ⁶ Causative germline mutation ⁵⁹ Genetic Tests ²⁹ Susceptibility factor ⁵⁷ DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)	20963938 22138009 23970018 (more) 21670465 20040766 21765025 21242295 21892162
3	FLT3	Fms Related Tyrosine Kinase 3	Protein Coding	1376.56	Molecular basis known ⁵⁷ Pathogenic ⁶ Causative somatic mutation ⁵⁹ Genetic Tests ²⁹ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	11290608 14670924 20963938 (more) 22138009 23970018 11442493 12384447
4	JAK2	Janus Kinase 2	Protein Coding	1306.79	Molecular basis known ⁵⁷ Pathogenic ⁶ Causative variation ⁷⁵ Genetic Tests ²⁹ DISEASES inferred ¹⁵	16247455 20963938 22138009 (more) 23970018
5	NPM1	Nucleophosmin 1	Protein Coding	1025.75	Molecular basis known ⁵⁷ Pathogenic ⁶ Genetic Tests ²⁹ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	15659725 20963938 22138009 (more) 23970018
6	KIT	KIT Proto-Oncogene Receptor Tyrosine Kinase	Protein Coding	1025.43	Molecular basis known ⁵⁷ Pathogenic/Likely pathogenic ⁶ Genetic Tests ²⁹ DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)	7513208 9657776 8589724 (more) 19865100 20963938 22138009 23970018
	KIT::MIR221 ⁴⁷	MIR221 Macro RNA (hsa-miR-221) targets KIT
	KIT::MIR222 ⁴⁷	MIR222 Macro RNA (hsa-miR-222) targets KIT
7	DNMT3A	DNA Methyltransferase 3 Alpha	Protein Coding	1007.88	Molecular basis known ⁵⁷ Pathogenic ⁶ Genetic Tests ²⁹ DISEASES inferred ¹⁵	20963938 22138009 23970018
8	ETV6	ETS Variant 6	Protein Coding	1006.47	Molecular basis known ⁵⁷ Pathogenic ⁶ Genetic Tests ²⁹ DISEASES inferred ¹⁵	15806161 20963938 22138009 (more) 23970018
9	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	1004.57	Molecular basis known ⁵⁷ Pathogenic ⁶ Genetic Tests ²⁹ DISEASES inferred ¹⁵	8955068 20963938 22138009 (more) 23970018
10	TGM6	Transglutaminase 6	Protein Coding	750	Pathogenic ⁶ Causative germline mutation ⁵⁹	20963938 22138009 23970018
11	TERT	Telomerase Reverse Transcriptase	Protein Coding	697.1	Molecular basis known ⁵⁷ Genetic Tests ²⁹ Susceptibility factor ⁵⁷ Risk factor ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)	19147845 20963938 22138009 (more) 23970018
12	CHIC2	Cysteine Rich Hydrophobic Domain 2	Protein Coding	653.28	Molecular basis known ⁵⁷ Genetic Tests ²⁹ Susceptibility factor ⁵⁷ DISEASES inferred ¹⁵
13	RUNX1	Runt Related Transcription Factor 1	Protein Coding	635	Molecular basis known ⁵⁷ Genetic Tests ²⁹ DISEASES inferred ¹⁵ GeneCards inferred via : Publications Variants (show sections)
14	PICALM	Phosphatidylinositol Binding Clathrin Assembly Protein	Protein Coding	622	Molecular basis known ⁵⁷ Genetic Tests ²⁹ DISEASES inferred ¹⁵ GeneCards inferred via : Summaries (show sections)
15	MLLT10	MLLT10, Histone Lysine Methyltransferase DOT1L Cofactor	Protein Coding	606.67	Molecular basis known ⁵⁷ Genetic Tests ²⁹ DISEASES inferred ¹⁵
16	NUP214	Nucleoporin 214	Protein Coding	606.05	Molecular basis known ⁵⁷ Genetic Tests ²⁹ DISEASES inferred ¹⁵
17	LPP	LIM Domain Containing Preferred Translocation Partner In Lipoma	Protein Coding	600	Molecular basis known ⁵⁷ Genetic Tests ²⁹
18	NRAS	NRAS Proto-Oncogene, GTPase	Protein Coding	424.65	Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)	20963938 22138009 23970018
19	CSF3R	Colony Stimulating Factor 3 Receptor	Protein Coding	424.23	Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)	20963938 22138009 23970018
20	PTPN11	Protein Tyrosine Phosphatase, Non-Receptor Type 11	Protein Coding	423.68	Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)	20963938 22138009 23970018
21	IDH2	Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial	Protein Coding	407.6	Pathogenic ⁶ DISEASES inferred ¹⁵	20963938 22138009 23970018
22	IDH1	Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic	Protein Coding	407.57	Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵	20963938 22138009 23970018
23	TP53	Tumor Protein P53	Protein Coding	406.7	Pathogenic ⁶ DISEASES inferred ¹⁵	20963938 22138009 23970018
24	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	406.43	Pathogenic ⁶ DISEASES inferred ¹⁵	20963938 22138009 23970018
25	DDX41	DEAD-Box Helicase 41	Protein Coding	403.8	Pathogenic ⁶ DISEASES inferred ¹⁵	20963938 22138009 23970018
26	SF3B1	Splicing Factor 3b Subunit 1	Protein Coding	400	Pathogenic ⁶	20963938 22138009 23970018
27	KMT2A	Lysine Methyltransferase 2A	Protein Coding	374.42	Gene fusion ⁵⁹ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
28	TET2	Tet Methylcytosine Dioxygenase 2	Protein Coding	358.33	Causative somatic mutation ⁵⁹ DISEASES inferred ¹⁵
29	MIR126	MicroRNA 126	RNA Gene	350	Causal ⁴⁷	18832181
30	MIR320A	MicroRNA 320a	RNA Gene	350	Causal ⁴⁷	19135902
31	MIR34B	MicroRNA 34b	RNA Gene	350	Causal ⁴⁷	19258499
32	MIR204	MicroRNA 204	RNA Gene	350	Causal ⁴⁷	18308931
33	SETBP1	SET Binding Protein 1	Protein Coding	304.55	Causative variation ⁷⁵ DISEASES inferred ¹⁵
34	MLF1	Myeloid Leukemia Factor 1	Protein Coding	156	Genetic Tests ²⁹ Genetic association ⁵⁷ DISEASES inferred ¹⁵
35	NSD1	Nuclear Receptor Binding SET Domain Protein 1	Protein Coding	155.75	Genetic Tests ²⁹ Genetic association ⁵⁷ DISEASES inferred ¹⁵
36	SH3GL1	SH3 Domain Containing GRB2 Like 1, Endophilin A2	Protein Coding	154.58	Genetic Tests ²⁹ Genetic association ⁵⁷ DISEASES inferred ¹⁵
37	CBFB	Core-Binding Factor Subunit Beta	Protein Coding	154.44	Genetic Tests ²⁹ Genetic association ⁵⁷ DISEASES inferred ¹⁵
38	HOTAIRM1	HOXA Transcript Antisense RNA, Myeloid-Specific 1	RNA Gene	154.18	Experimental evidence: Locus ³⁹ DISEASES inferred ¹⁵	26436590
39	IRAIN	IGF1R Antisense Imprinted Non-Protein Coding RNA	RNA Gene	154.13	Experimental evidence: Regulation ³⁹ DISEASES inferred ¹⁵	25092925
40	CCDC26	CCDC26 Long Non-Coding RNA	RNA Gene	153.89	Experimental evidence: Regulation ³⁹ DISEASES inferred ¹⁵	25928165
41	WT1-AS	WT1 Antisense RNA	RNA Gene	153.11	Experimental evidence: Regulation ³⁹ DISEASES inferred ¹⁵	17940140 10340388
42	HOTAIR	HOX Transcript Antisense RNA	RNA Gene	150	Experimental evidence: Expression ³⁹	28669171 26622861 26261618 (more) 25979172
43	CDKN2B-AS1	CDKN2B Antisense RNA 1	RNA Gene	150	Experimental evidence: Regulation ³⁹	21414664 18185590
44	UCA1	Urothelial Cancer Associated 1	RNA Gene	150	Experimental evidence: Regulation ³⁹	26053097
45	TUSC7	Tumor Suppressor Candidate 7	RNA Gene	150	Experimental evidence: Expression ³⁹	26345353
46	TUG1	Taurine Up-Regulated 1	RNA Gene	150	Experimental evidence: Expression ³⁹	29654398
47	MEG3	Maternally Expressed 3	RNA Gene	150	Experimental evidence: Regulation ³⁹	19595458
48	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1	RNA Gene	150	Experimental evidence: Expression ³⁹	28713913
49	CCAT1	Colon Cancer Associated Transcript 1	RNA Gene	150	Experimental evidence: Regulation ³⁹	26923190
50	NSD3	Nuclear Receptor Binding SET Domain Protein 3	Protein Coding	104.21	Genetic Tests ²⁹ DISEASES inferred ¹⁵

Sources

Variations for Leukemia, Acute Myeloid

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Acute Myeloid:

⁷⁵

#	Symbol	AA change	Variation ID	SNP ID
1	CEBPA	p.His84Leu	VAR_072677	rs28931590
2	JAK2	p.Lys607Asn	VAR_032696	rs121912472
3	JAK2	p.Val617Phe	VAR_032697	rs77375493
4	SETBP1	p.Gly870Ser	VAR_063809	rs267607040
5	SETBP1	p.Ser854Ala	VAR_069848
6	SETBP1	p.Gly870Arg	VAR_069854
7	SETBP1	p.Ile871Ser	VAR_069856

ClinVar genetic disease variations for Leukemia, Acute Myeloid:

⁶ (show top 50) (show all 750)

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	ETV6	NM_001987.4(ETV6): c.226G> T (p.Glu76Ter)	single nucleotide variant	Pathogenic	rs121434637	GRCh37	Chromosome 12, 11992136: 11992136
2	ETV6	NM_001987.4(ETV6): c.226G> T (p.Glu76Ter)	single nucleotide variant	Pathogenic	rs121434637	GRCh38	Chromosome 12, 11839202: 11839202
3	ETV6	NM_001987.4(ETV6): c.1307_1308insGGG (p.His436delinsGlnGly)	insertion	Pathogenic	rs587776710	GRCh37	Chromosome 12, 12043928: 12043929
4	ETV6	NM_001987.4(ETV6): c.1307_1308insGGG (p.His436delinsGlnGly)	insertion	Pathogenic	rs587776710	GRCh38	Chromosome 12, 11890994: 11890995
5	TP53	NM_000546.5(TP53): c.742C> T (p.Arg248Trp)	single nucleotide variant	Pathogenic	rs121912651	GRCh37	Chromosome 17, 7577539: 7577539
6	TP53	NM_000546.5(TP53): c.742C> T (p.Arg248Trp)	single nucleotide variant	Pathogenic	rs121912651	GRCh38	Chromosome 17, 7674221: 7674221
7	TP53	NM_000546.5(TP53): c.743G> A (p.Arg248Gln)	single nucleotide variant	Pathogenic/Likely pathogenic	rs11540652	GRCh37	Chromosome 17, 7577538: 7577538
8	TP53	NM_000546.5(TP53): c.743G> A (p.Arg248Gln)	single nucleotide variant	Pathogenic/Likely pathogenic	rs11540652	GRCh38	Chromosome 17, 7674220: 7674220
9	TP53	NM_000546.5(TP53): c.818G> A (p.Arg273His)	single nucleotide variant	Pathogenic/Likely pathogenic	rs28934576	GRCh37	Chromosome 17, 7577120: 7577120
10	TP53	NM_000546.5(TP53): c.818G> A (p.Arg273His)	single nucleotide variant	Pathogenic/Likely pathogenic	rs28934576	GRCh38	Chromosome 17, 7673802: 7673802
11	TP53	NM_000546.5(TP53): c.839G> C (p.Arg280Thr)	single nucleotide variant	Uncertain significance	rs121912660	GRCh37	Chromosome 17, 7577099: 7577099
12	TP53	NM_000546.5(TP53): c.839G> C (p.Arg280Thr)	single nucleotide variant	Uncertain significance	rs121912660	GRCh38	Chromosome 17, 7673781: 7673781
13	KRAS	NM_033360.3(KRAS): c.38G> A (p.Gly13Asp)	single nucleotide variant	Pathogenic	rs112445441	GRCh37	Chromosome 12, 25398281: 25398281
14	KRAS	NM_033360.3(KRAS): c.38G> A (p.Gly13Asp)	single nucleotide variant	Pathogenic	rs112445441	GRCh38	Chromosome 12, 25245347: 25245347
15	KRAS	NM_004985.4(KRAS): c.35G> A (p.Gly12Asp)	single nucleotide variant	Pathogenic	rs121913529	GRCh37	Chromosome 12, 25398284: 25398284
16	KRAS	NM_004985.4(KRAS): c.35G> A (p.Gly12Asp)	single nucleotide variant	Pathogenic	rs121913529	GRCh38	Chromosome 12, 25245350: 25245350
17	KRAS	NM_004985.4(KRAS): c.35G> T (p.Gly12Val)	single nucleotide variant	Pathogenic	rs121913529	GRCh37	Chromosome 12, 25398284: 25398284
18	KRAS	NM_004985.4(KRAS): c.35G> T (p.Gly12Val)	single nucleotide variant	Pathogenic	rs121913529	GRCh38	Chromosome 12, 25245350: 25245350
19	KRAS	NM_004985.4(KRAS): c.27_29dupTGG (p.Gly10_Ala11insGly)	duplication	Pathogenic	rs606231202	GRCh38	Chromosome 12, 25245356: 25245358
20	KRAS	NM_004985.4(KRAS): c.27_29dupTGG (p.Gly10_Ala11insGly)	duplication	Pathogenic	rs606231202	GRCh37	Chromosome 12, 25398290: 25398292
21	HRAS	NM_005343.3(HRAS): c.34G> A (p.Gly12Ser)	single nucleotide variant	Pathogenic	rs104894229	GRCh37	Chromosome 11, 534289: 534289
22	HRAS	NM_005343.3(HRAS): c.34G> A (p.Gly12Ser)	single nucleotide variant	Pathogenic	rs104894229	GRCh38	Chromosome 11, 534289: 534289
23	HRAS	NM_005343.3(HRAS): c.35G> C (p.Gly12Ala)	single nucleotide variant	Pathogenic	rs104894230	GRCh37	Chromosome 11, 534288: 534288
24	HRAS	NM_005343.3(HRAS): c.35G> C (p.Gly12Ala)	single nucleotide variant	Pathogenic	rs104894230	GRCh38	Chromosome 11, 534288: 534288
25	HRAS	NM_005343.3(HRAS): c.436G> A (p.Ala146Thr)	single nucleotide variant	Pathogenic/Likely pathogenic	rs104894231	GRCh38	Chromosome 11, 533467: 533467
26	HRAS	NM_005343.3(HRAS): c.37G> T (p.Gly13Cys)	single nucleotide variant	Pathogenic	rs104894228	GRCh37	Chromosome 11, 534286: 534286
27	HRAS	NM_005343.3(HRAS): c.37G> T (p.Gly13Cys)	single nucleotide variant	Pathogenic	rs104894228	GRCh38	Chromosome 11, 534286: 534286
28	HRAS	NM_005343.3(HRAS): c.436G> A (p.Ala146Thr)	single nucleotide variant	Pathogenic/Likely pathogenic	rs104894231	GRCh37	Chromosome 11, 533467: 533467
29	HRAS	NM_005343.3(HRAS): c.437C> T (p.Ala146Val)	single nucleotide variant	Likely pathogenic	rs121917759	GRCh37	Chromosome 11, 533466: 533466
30	HRAS	NM_005343.3(HRAS): c.437C> T (p.Ala146Val)	single nucleotide variant	Likely pathogenic	rs121917759	GRCh38	Chromosome 11, 533466: 533466
31	HRAS	NM_005343.3(HRAS): c.34G> T (p.Gly12Cys)	single nucleotide variant	Pathogenic	rs104894229	GRCh37	Chromosome 11, 534289: 534289
32	HRAS	NM_005343.3(HRAS): c.34G> T (p.Gly12Cys)	single nucleotide variant	Pathogenic	rs104894229	GRCh38	Chromosome 11, 534289: 534289
33	KIT	NM_000222.2(KIT): c.2447A> T (p.Asp816Val)	single nucleotide variant	Uncertain significance	rs121913507	GRCh37	Chromosome 4, 55599321: 55599321
34	KIT	NM_000222.2(KIT): c.2447A> T (p.Asp816Val)	single nucleotide variant	Uncertain significance	rs121913507	GRCh38	Chromosome 4, 54733155: 54733155
35	KIT	NM_000222.2(KIT): c.2446G> T (p.Asp816Tyr)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913506	GRCh37	Chromosome 4, 55599320: 55599320
36	KIT	NM_000222.2(KIT): c.2446G> T (p.Asp816Tyr)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913506	GRCh38	Chromosome 4, 54733154: 54733154
37	KIT	NM_000222.2(KIT): c.2446G> C (p.Asp816His)	single nucleotide variant	Pathogenic	rs121913506	GRCh37	Chromosome 4, 55599320: 55599320
38	KIT	NM_000222.2(KIT): c.2446G> C (p.Asp816His)	single nucleotide variant	Pathogenic	rs121913506	GRCh38	Chromosome 4, 54733154: 54733154
39	NRAS	NM_002524.4(NRAS): c.37G> C (p.Gly13Arg)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121434595	GRCh37	Chromosome 1, 115258745: 115258745
40	NRAS	NM_002524.4(NRAS): c.37G> C (p.Gly13Arg)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121434595	GRCh38	Chromosome 1, 114716124: 114716124
41	NRAS	NM_002524.4(NRAS): c.182A> G (p.Gln61Arg)	single nucleotide variant	Pathogenic	rs11554290	GRCh37	Chromosome 1, 115256529: 115256529
42	NRAS	NM_002524.4(NRAS): c.182A> G (p.Gln61Arg)	single nucleotide variant	Pathogenic	rs11554290	GRCh38	Chromosome 1, 114713908: 114713908
43	NRAS	NM_002524.4(NRAS): c.38G> A (p.Gly13Asp)	single nucleotide variant	Pathogenic	rs121434596	GRCh37	Chromosome 1, 115258744: 115258744
44	NRAS	NM_002524.4(NRAS): c.38G> A (p.Gly13Asp)	single nucleotide variant	Pathogenic	rs121434596	GRCh38	Chromosome 1, 114716123: 114716123
45	NPM1	NM_002520.6(NPM1): c.860_863dupTCTG (p.Trp288Cysfs)	duplication	Pathogenic	rs587776806	GRCh38	Chromosome 5, 171410540: 171410543
46	NPM1	NM_002520.6(NPM1): c.860_863dupTCTG (p.Trp288Cysfs)	duplication	Pathogenic	rs587776806	GRCh37	Chromosome 5, 170837544: 170837547
47	NPM1	NM_002520.6(NPM1): c.863_864insCATG (p.Trp288Cysfs)	insertion	Pathogenic	rs587776806	GRCh38	Chromosome 5, 171410543: 171410544
48	NPM1	NM_002520.6(NPM1): c.863_864insCATG (p.Trp288Cysfs)	insertion	Pathogenic	rs587776806	GRCh37	Chromosome 5, 170837547: 170837548
49	NPM1	NM_002520.6(NPM1): c.863_864insCGTG (p.Trp288Cysfs)	insertion	Pathogenic	rs587776806	GRCh38	Chromosome 5, 171410543: 171410544
50	NPM1	NM_002520.6(NPM1): c.863_864insCGTG (p.Trp288Cysfs)	insertion	Pathogenic	rs587776806	GRCh37	Chromosome 5, 170837547: 170837548

Copy number variations for Leukemia, Acute Myeloid from CNVD:

⁷ (show top 50) (show all 491)

#	CNVD ID	Chromosom	Start	End	Type	Gene Symbol	CNVD Disease
1	13336	1	1	124300000	Insertion		Acute myeloid leukemia
2	13759	1	1	28000000	Deletion		Acute myeloid leukemia
3	14790	1	110122000	110569000	Gain or loss		Acute myeloid leukemia
4	17466	1	142902432	245422360	Duplication		Acute myeloid leukemia
5	18096	1	143961000	247125000	Gain or loss		Acute myeloid leukemia
6	20826	1	154656757	154656845	Amplification		Acute myeloid leukemia
7	24589	1	182359000	182787000	Loss		Acute myeloid leukemia
8	26098	1	197094625	197094734	Amplification		Acute myeloid leukemia
9	26100	1	197094796	197094905	Amplification		Acute myeloid leukemia
10	27148	1	204981000	205049000	Gain or loss		Acute myeloid leukemia
11	27263	1	206041820	206041907	Amplification		Acute myeloid leukemia
12	27859	1	214500000	224100000	Deletion		Acute myeloid leukemia
13	28491	1	222606000	222909000	Gain or loss		Acute myeloid leukemia
14	29341	1	230606000	230646000	Gain or loss		Acute myeloid leukemia
15	32943	1	40683565	40683656	Amplification		Acute myeloid leukemia
16	32944	1	40686494	40686582	Amplification		Acute myeloid leukemia
17	33084	1	42072000	42456000	Gain or loss		Acute myeloid leukemia
18	35033	1	5913000	7696000	Gain or loss		Acute myeloid leukemia
19	35608	1	65296705	65296779	Amplification		Acute myeloid leukemia
20	35769	1	67074000	69951000	Gain or loss		Acute myeloid leukemia
21	36085	1	71305902	71305987	Amplification	miR-186	Acute myeloid leukemia
22	38187	10	1	6700000	Insertion	IL15RA	Acute myeloid leukemia
23	38188	10	1	6700000	Insertion	PRKCQ	Acute myeloid leukemia
24	38677	10	104186259	104186331	Deletion		Acute myeloid leukemia
25	38804	10	105144000	105144148	Deletion		Acute myeloid leukemia
26	39144	10	110889374	110889450	Deletion		Acute myeloid leukemia
27	39902	10	122017230	122017301	Deletion	let-7a-2	Acute myeloid leukemia
28	41668	10	21893278	22027081	Loss	MLLT10	Acute myeloid leukemia
29	41990	10	27075530	27189965	Translate	SSH3BP1	Acute myeloid leukemia
30	43278	10	46100000	49900000	Copy number	GDF10	Acute myeloid leukemia
31	44445	10	57165247	57165335	Deletion		Acute myeloid leukemia
32	44874	11	64658609	64658718	Deletion	miR-192	Acute myeloid leukemia
33	45369	10	70521000	135283000	Gain		Acute myeloid leukemia
34	47681	10	96486000	100815000	Loss		Acute myeloid leukemia
35	49592	11	108316750	133951370	Triplication		Acute myeloid leukemia
36	50142	11	114500000	121200000	Copy number	MLL	Acute myeloid leukemia
37	50190	11	115400000	120700000	Insertion	DDX6	Acute myeloid leukemia
38	50191	11	115400000	120700000	Insertion	ETS1	Acute myeloid leukemia
39	50192	11	115400000	120700000	Insertion	FLI1	Acute myeloid leukemia
40	50193	11	115400000	120700000	Insertion	MLL	Acute myeloid leukemia
41	50261	11	116297361	116448564	Loss		Acute myeloid leukemia
42	50346	11	117203762	118563610	Amplification		Acute myeloid leukemia
43	50385	11	117603158	117860329	Duplication		Acute myeloid leukemia
44	50437	11	117820656	117856311	Gain	MLL	Acute myeloid leukemia
45	50640	11	118585028	127052111	Deletion		Acute myeloid leukemia
46	51468	11	126537000	130235000	Gain		Acute myeloid leukemia
47	51512	11	127394408	133951311	Amplification		Acute myeloid leukemia
48	52810	11	2016406	2019065	Methylation	H19	Acute myeloid leukemia
49	53744	11	32409321	32457081	Mutation	WT1	Acute myeloid leukemia
50	54217	11	39671000	39746000	Loss		Acute myeloid leukemia

Sources

Expression for Leukemia, Acute Myeloid

Search GEO for disease gene expression data for Leukemia, Acute Myeloid.

Sources

Pathways for Leukemia, Acute Myeloid

Pathways related to Leukemia, Acute Myeloid according to KEGG:

³⁷

#	Name	Kegg Source Accession
1	Acute myeloid leukemia	hsa05221
2	Transcriptional misregulation in cancer	hsa05202

Pathways related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

(show all 27)

#	Super pathways	Score	Top Affiliating Genes
1	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.3	CEBPA CSF3R FLT3 JAK2 KIT KRAS
2	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.17	CSF3R FLT3 JAK2 KIT KRAS NRAS
3	PI3K-Akt signaling pathway ³⁷ Show member pathways Human papillomavirus infection ³⁷	12.75	CSF3R FLT3 JAK2 KIT KRAS NRAS
4	Ras signaling pathway ³⁷ Show member pathways Rap1 signaling pathway ³⁷	12.56	FLT3 KIT KRAS NRAS PTPN11
5	Endometrial cancer ³⁷ Show member pathways Acute myeloid leukemia ³⁷ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁶ Chronic myeloid leukemia ³⁷ Colorectal cancer ³⁷ Pancreatic cancer ³⁷ Prostate cancer ³⁷ Signal transduction PTEN pathway ²² Thyroid cancer ³⁷	12.44	CEBPA FLT3 KIT KRAS NRAS PTPN11
6	NF-kappaB Signaling ⁴	12.39	CEBPA GATA2 JAK2 KIT RUNX1
7	Prolactin Signaling Pathway ¹ ³⁷ Show member pathways Development Prolactin receptor signaling ²² Leptin signaling pathway ¹	12.38	JAK2 KRAS NRAS PTPN11
8	Development FGFR signaling pathway ²² Show member pathways Development FGF-family signaling ²² Development Flt3 signaling ²² FGF Pathway ⁶⁴	12.32	FLT3 KRAS NRAS PTPN11
9	Phospholipase D signaling pathway ³⁷ Show member pathways Choline metabolism in cancer ³⁷	12.27	KIT KRAS NRAS PTPN11
10	CNTF Signaling ⁶⁴ Show member pathways FLT3 Signaling ⁶⁴ IL-3 Pathway ⁶⁴ Nur77-Induced AICD in Macrophage ⁶⁴ OSM Pathway ⁶⁴	12.2	FLT3 JAK2 KRAS NRAS
11	JAK-STAT signaling pathway (KEGG) ³⁷ Show member pathways Interleukin-19, 20, 22, 24 ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵	12.2	CSF3R JAK2 KRAS NRAS PTPN11
12	G-protein signaling Ras family GTPases in kinase cascades (scheme) ²² Show member pathways Activation of the AP-1 family of transcription factors ⁶⁶ Immune response Oncostatin M signaling via MAPK in human cells ²² MAPK Cascade ¹ Oncostatin M Signaling Pathway ¹	12.12	JAK2 KRAS NRAS PTPN11
13	Transcriptional misregulation in cancer ³⁷	12.08	CEBPA ETV6 FLT3 RUNX1
14	Pathways in cancer ³⁷	12	CEBPA CSF3R FLT3 JAK2 KIT KRAS
15	Tyrosine Kinases / Adaptors ⁴	11.97	FLT3 JAK2 KIT NPM1
16	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ¹ Nuclear signaling by ERBB4 ⁶⁶	11.84	JAK2 KRAS NRAS
17	AGE-RAGE signaling pathway in diabetic complications ³⁷	11.8	JAK2 KRAS NRAS
18	Hematopoietic cell lineage ³⁷	11.78	CSF3R FLT3 KIT
19	C-MYB transcription factor network ¹	11.64	CEBPA KIT NRAS
20	HIF-1-alpha transcription factor network ¹	11.54	GATA2 NPM1 TERT
21	VEGF Pathway (Tocris) ⁶¹ Show member pathways VEGF Pathway ⁷²	11.54	FLT3 KIT KRAS NRAS
22	Negative regulation of MAPK pathway ⁶⁶ Show member pathways RAF activation ⁶⁶	11.53	JAK2 KRAS NRAS
23	Central carbon metabolism in cancer ³⁷	11.37	FLT3 KIT KRAS NRAS
24	Jak-Stat Signaling Pathway (sino) ⁶⁷	11.3	CSF3R JAK2 KRAS NRAS PTPN11
25	Transcription_Transcription factor Tubby signaling pathways ²²	11.19	JAK2 KRAS NRAS
26	Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex ¹	10.92	DNMT3A ETV6 FLT3
27	p38MAPK events ⁶⁶	10.71	KRAS NRAS

Sources

GO Terms for Leukemia, Acute Myeloid

Cellular components related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	nucleoplasm	GO:0005654	9.85	CEBPA DNMT3A GATA2 JAK2 MLLT10 NPM1
2	nucleus	GO:0005634	9.8	CEBPA DNMT3A ETV6 FLT3 GATA2 JAK2
3	focal adhesion	GO:0005925	9.02	JAK2 KRAS LPP NPM1 NUP214
4	cytosol	GO:0005829	10.03	ETV6 FLT3 JAK2 KRAS LPP MLLT10

Biological processes related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

(show all 14)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of cell proliferation	GO:0008284	9.91	FLT3 JAK2 KIT KRAS NPM1
2	negative regulation of gene expression	GO:0010629	9.78	GATA2 PICALM RUNX1 TERT
3	positive regulation of phosphatidylinositol 3-kinase signaling	GO:0014068	9.61	FLT3 JAK2 KIT
4	positive regulation of tyrosine phosphorylation of STAT protein	GO:0042531	9.58	FLT3 JAK2 KIT
5	MAPK cascade	GO:0000165	9.55	FLT3 JAK2 KIT KRAS NRAS
6	interleukin-6-mediated signaling pathway	GO:0070102	9.54	JAK2 PTPN11
7	positive regulation of MAP kinase activity	GO:0043406	9.54	FLT3 KIT KRAS
8	megakaryocyte development	GO:0035855	9.52	KIT PTPN11
9	hematopoietic stem cell proliferation	GO:0071425	9.49	ETV6 RUNX1
10	regulation of myeloid cell differentiation	GO:0045637	9.46	CSF3R RUNX1
11	homeostasis of number of cells within a tissue	GO:0048873	9.43	GATA2 KRAS PTPN11
12	hemopoiesis	GO:0030097	9.35	FLT3 GATA2 KIT PICALM RUNX1
13	myeloid progenitor cell differentiation	GO:0002318	9.32	FLT3 KIT
14	cytokine-mediated signaling pathway	GO:0019221	9.17	CEBPA CSF3R FLT3 JAK2 KIT KRAS

Molecular functions related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein binding	GO:0005515	9.6	CEBPA CHIC2 CSF3R DNMT3A ETV6 FLT3
2	RNA polymerase II proximal promoter sequence-specific DNA binding	GO:0000978	9.55	CEBPA DNMT3A ETV6 GATA2 RUNX1
3	nucleotide binding	GO:0000166	9.35	FLT3 JAK2 KIT KRAS NRAS
4	insulin receptor substrate binding	GO:0043560	9.32	JAK2 PTPN11
5	peptide hormone receptor binding	GO:0051428	9.26	JAK2 PTPN11

Sources

Sources for Leukemia, Acute Myeloid

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia

Leukemia, Acute Myeloid (AML)

Aliases & Classifications for Leukemia, Acute Myeloid

MalaCards integrated aliases for Leukemia, Acute Myeloid:

Characteristics:

Orphanet epidemiological data:

OMIM:

HPO:

Classifications:

External Ids:

Summaries for Leukemia, Acute Myeloid

Related Diseases for Leukemia, Acute Myeloid

Diseases in the Myeloid Leukemia family:

Diseases related to Leukemia, Acute Myeloid via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Leukemia, Acute Myeloid:

Symptoms & Phenotypes for Leukemia, Acute Myeloid

Symptoms via clinical synopsis from OMIM:

Clinical features from OMIM:

Human phenotypes related to Leukemia, Acute Myeloid:

UMLS symptoms related to Leukemia, Acute Myeloid:

GenomeRNAi Phenotypes related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

MGI Mouse Phenotypes related to Leukemia, Acute Myeloid:

Drugs & Therapeutics for Leukemia, Acute Myeloid

FDA approved drugs:

Drugs for Leukemia, Acute Myeloid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 73 / NDF-RT 51 :

Cell-based therapeutics:

Cochrane evidence based reviews: leukemia, myeloid, acute

Genetic Tests for Leukemia, Acute Myeloid

Genetic tests related to Leukemia, Acute Myeloid:

Anatomical Context for Leukemia, Acute Myeloid

MalaCards organs/tissues related to Leukemia, Acute Myeloid:

Publications for Leukemia, Acute Myeloid

Articles related to Leukemia, Acute Myeloid:

Genes for Leukemia, Acute Myeloid

Genes related to Leukemia, Acute Myeloid (38 elite genes):

Variations for Leukemia, Acute Myeloid

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Acute Myeloid:

ClinVar genetic disease variations for Leukemia, Acute Myeloid:

Copy number variations for Leukemia, Acute Myeloid from CNVD:

Expression for Leukemia, Acute Myeloid

Pathways for Leukemia, Acute Myeloid

Pathways related to Leukemia, Acute Myeloid according to KEGG:

Pathways related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

GO Terms for Leukemia, Acute Myeloid

Cellular components related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

Biological processes related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

Molecular functions related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

Sources for Leukemia, Acute Myeloid

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :